Variety of qualified patients: CDEC mentioned the uncertainty in the amount of individuals with moderately serious to extreme hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific specialists consulted by CADTH indicated that some individuals who are categorised as owning moderate or reasonable ailment could have a significant b